Baltimore City Receives $80 Million in Opioid Crisis Settlement from Teva Pharmaceuticals
Significant Opioid Settlement for Baltimore City
BALTIMORE -- The City of Baltimore has reached a groundbreaking $80 million settlement with Teva Pharmaceuticals over the company's role in the city's ongoing opioid crisis, announced city officials Monday. Teva will pay an initial $35 million by the end of this year, with the remaining funds due by July 1, 2025. This settlement marks the fourth major agreement in Baltimore's litigation against opioid distributors and manufacturers.
Prior Settlements Enhance Recovery Efforts
The city has previously secured $45 million from Allergan, $45 million from CVS, and $152.5 million from Cardinal Health. These recoveries have significantly bolstered Baltimore's efforts to address the devastating impact of the opioid crisis, bringing total funds recovered from opioid defendants to $322.5 million.
Disclaimer: The information provided on this site is for informational purposes only and is not intended as medical advice. We are not responsible for any actions taken based on the content of this site. Always consult a qualified healthcare provider for medical advice, diagnosis, and treatment. We source our news from reputable sources and provide links to the original articles. We do not endorse or assume responsibility for the accuracy of the information contained in external sources.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.